A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Clinical trial NCT07016412 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07016412
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-31
- Primary completion
- 2026-08-17
- Enrollment
- 1119
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.